Champions Oncology Inc (NASDAQ:CSBR) has been assigned an average recommendation of “Buy” from the six research firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $13.00.

Several brokerages have issued reports on CSBR. Zacks Investment Research upgraded Champions Oncology from a “strong sell” rating to a “hold” rating in a report on Monday, March 18th. National Securities began coverage on Champions Oncology in a report on Wednesday, February 27th. They issued a “buy” rating and a $17.00 price target on the stock.

Large investors have recently made changes to their positions in the business. Squarepoint Ops LLC bought a new position in Champions Oncology in the fourth quarter worth approximately $185,000. Sandy Spring Bank bought a new position in shares of Champions Oncology in the fourth quarter valued at approximately $205,000. Alambic Investment Management L.P. bought a new position in shares of Champions Oncology in the fourth quarter valued at approximately $215,000. Northern Trust Corp lifted its holdings in shares of Champions Oncology by 7.9% in the fourth quarter. Northern Trust Corp now owns 27,730 shares of the biotechnology company’s stock valued at $217,000 after purchasing an additional 2,028 shares in the last quarter. Finally, Oberweis Asset Management Inc. bought a new position in shares of Champions Oncology in the fourth quarter valued at approximately $291,000. Institutional investors and hedge funds own 51.96% of the company’s stock.

Shares of NASDAQ:CSBR opened at $7.51 on Thursday. The company has a market capitalization of $90.91 million, a price-to-earnings ratio of -53.64 and a beta of 1.50. Champions Oncology has a 52-week low of $3.73 and a 52-week high of $17.90.

Champions Oncology Company Profile

Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.

Featured Story: What is a growth and income fund?

Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.